Open AccessAbstract CT166: TRX-E-002-1 in treatment-refractory ovarian cancer - 3-month follow-up results from a phase I study dose escalation phase
Author(s) -
Jermaine Coward,
Ganessan Kichenadasse,
Paul Harnett,
Kathleen Moore,
Minal Barve,
Daniel Berg,
James S. Garner,
Don S. Dizon
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct166
Subject(s) - medicine , ovarian cancer , oncology , chemotherapy , cd44 , cancer , refractory (planetary science) , cell , genetics , biology , physics , astrobiology